Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)

Christine Gan; Amit Patel; Sarah Fowler; James Catto; Derek Rosario; Tim O'Brien

doi:10.1111/bju.12235

Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)

Christine Gan, Amit Patel, Sarah Fowler, James Catto, Derek Rosario, Tim O'Brien

British Association of Urological Surgeons

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Objectives

To determine the quality of transurethral resection of bladder tumour (TURBT) in the UK.

To evaluate the utility of a novel snapshot' methodology in carrying out national audits.

Patients and Methods

Every consultant Urologist in the UK was asked to contribute details of their first patient with a new bladder cancer treated with TURBT after midnight of 31st January 2010.

Responses were received from 192 consultants.

Results

The median (range) time from referral to first Urology appointment was 11 (0-161) days, and the median (range) time from first appointment to TURBT was 27 (1-588) days.

In all, 12 (6.3%) patients underwent photodynamic diagnosis-assisted TURBT and 119 patients (61%) received a dose of Mitomycin C after TURBT.

The rate of major complications was low, with five incidences (2.6%) of bladder perforation.

There was no record of muscle present in resected specimens in 40 cases (20.8%) and resection was considered incomplete in 26 cases (13.5%). In all, 31 patients (16.1%) underwent early re-resection with residual tumour or carcinoma in situ detected in 17 cases, although no tumour was upstaged.

Of the 37 patients classified with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), there were nine recurrences (24.3%) at 3 months, and 13 recurrences (35.1%) at 1 year. Newly presenting MIBC managed with currently available treatments has a high mortality rate of 33.3% at 1 year.

Conclusions

The quality of TURBT in the UK is high.

Areas for improvement include the timeliness of diagnosis and treatment, and improved care of patients with intermediate-risk NMIBC and MIBC. The snapshot' methodology is promising but widening participation is a priority.

Original language	English
Pages (from-to)	930-935
Number of pages	6
Journal	BJU International
Volume	112
Issue number	7
DOIs	https://doi.org/10.1111/bju.12235
Publication status	Published - Nov 2013

Keywords

bladder cancer
transurethral resection of bladder tumour
quality
FOLLOW-UP
7 EORTC
CANCER
RECURRENCE
MUSCLE
RISK
PROGRESSION
CYSTOSCOPY
DIAGNOSIS
QUALITY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bju.12235

Cite this

@article{d5885e4bbe53475bb3ee3b261e922c39,

title = "Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)",

abstract = "ObjectivesTo determine the quality of transurethral resection of bladder tumour (TURBT) in the UK.To evaluate the utility of a novel snapshot' methodology in carrying out national audits.Patients and MethodsEvery consultant Urologist in the UK was asked to contribute details of their first patient with a new bladder cancer treated with TURBT after midnight of 31st January 2010.Responses were received from 192 consultants.ResultsThe median (range) time from referral to first Urology appointment was 11 (0-161) days, and the median (range) time from first appointment to TURBT was 27 (1-588) days.In all, 12 (6.3%) patients underwent photodynamic diagnosis-assisted TURBT and 119 patients (61%) received a dose of Mitomycin C after TURBT.The rate of major complications was low, with five incidences (2.6%) of bladder perforation.There was no record of muscle present in resected specimens in 40 cases (20.8%) and resection was considered incomplete in 26 cases (13.5%). In all, 31 patients (16.1%) underwent early re-resection with residual tumour or carcinoma in situ detected in 17 cases, although no tumour was upstaged.Of the 37 patients classified with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), there were nine recurrences (24.3%) at 3 months, and 13 recurrences (35.1%) at 1 year. Newly presenting MIBC managed with currently available treatments has a high mortality rate of 33.3% at 1 year.ConclusionsThe quality of TURBT in the UK is high.Areas for improvement include the timeliness of diagnosis and treatment, and improved care of patients with intermediate-risk NMIBC and MIBC. The snapshot' methodology is promising but widening participation is a priority.",

keywords = "bladder cancer, transurethral resection of bladder tumour, quality, FOLLOW-UP, 7 EORTC, CANCER, RECURRENCE, MUSCLE, RISK, PROGRESSION, CYSTOSCOPY, DIAGNOSIS, QUALITY",

author = "Christine Gan and Amit Patel and Sarah Fowler and James Catto and Derek Rosario and Tim O'Brien",

year = "2013",

month = nov,

doi = "10.1111/bju.12235",

language = "English",

volume = "112",

pages = "930--935",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)

AU - Gan, Christine

AU - Patel, Amit

AU - Fowler, Sarah

AU - Catto, James

AU - Rosario, Derek

AU - O'Brien , Tim

PY - 2013/11

Y1 - 2013/11

N2 - ObjectivesTo determine the quality of transurethral resection of bladder tumour (TURBT) in the UK.To evaluate the utility of a novel snapshot' methodology in carrying out national audits.Patients and MethodsEvery consultant Urologist in the UK was asked to contribute details of their first patient with a new bladder cancer treated with TURBT after midnight of 31st January 2010.Responses were received from 192 consultants.ResultsThe median (range) time from referral to first Urology appointment was 11 (0-161) days, and the median (range) time from first appointment to TURBT was 27 (1-588) days.In all, 12 (6.3%) patients underwent photodynamic diagnosis-assisted TURBT and 119 patients (61%) received a dose of Mitomycin C after TURBT.The rate of major complications was low, with five incidences (2.6%) of bladder perforation.There was no record of muscle present in resected specimens in 40 cases (20.8%) and resection was considered incomplete in 26 cases (13.5%). In all, 31 patients (16.1%) underwent early re-resection with residual tumour or carcinoma in situ detected in 17 cases, although no tumour was upstaged.Of the 37 patients classified with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), there were nine recurrences (24.3%) at 3 months, and 13 recurrences (35.1%) at 1 year. Newly presenting MIBC managed with currently available treatments has a high mortality rate of 33.3% at 1 year.ConclusionsThe quality of TURBT in the UK is high.Areas for improvement include the timeliness of diagnosis and treatment, and improved care of patients with intermediate-risk NMIBC and MIBC. The snapshot' methodology is promising but widening participation is a priority.

AB - ObjectivesTo determine the quality of transurethral resection of bladder tumour (TURBT) in the UK.To evaluate the utility of a novel snapshot' methodology in carrying out national audits.Patients and MethodsEvery consultant Urologist in the UK was asked to contribute details of their first patient with a new bladder cancer treated with TURBT after midnight of 31st January 2010.Responses were received from 192 consultants.ResultsThe median (range) time from referral to first Urology appointment was 11 (0-161) days, and the median (range) time from first appointment to TURBT was 27 (1-588) days.In all, 12 (6.3%) patients underwent photodynamic diagnosis-assisted TURBT and 119 patients (61%) received a dose of Mitomycin C after TURBT.The rate of major complications was low, with five incidences (2.6%) of bladder perforation.There was no record of muscle present in resected specimens in 40 cases (20.8%) and resection was considered incomplete in 26 cases (13.5%). In all, 31 patients (16.1%) underwent early re-resection with residual tumour or carcinoma in situ detected in 17 cases, although no tumour was upstaged.Of the 37 patients classified with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), there were nine recurrences (24.3%) at 3 months, and 13 recurrences (35.1%) at 1 year. Newly presenting MIBC managed with currently available treatments has a high mortality rate of 33.3% at 1 year.ConclusionsThe quality of TURBT in the UK is high.Areas for improvement include the timeliness of diagnosis and treatment, and improved care of patients with intermediate-risk NMIBC and MIBC. The snapshot' methodology is promising but widening participation is a priority.

KW - bladder cancer

KW - transurethral resection of bladder tumour

KW - quality

KW - FOLLOW-UP

KW - 7 EORTC

KW - CANCER

KW - RECURRENCE

KW - MUSCLE

KW - RISK

KW - PROGRESSION

KW - CYSTOSCOPY

KW - DIAGNOSIS

KW - QUALITY

U2 - 10.1111/bju.12235

DO - 10.1111/bju.12235

M3 - Article

SN - 1464-4096

VL - 112

SP - 930

EP - 935

JO - BJU International

JF - BJU International

IS - 7

ER -

Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this